<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Coccidioides immitis spherule-derived skin test antigen: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Coccidioides immitis spherule-derived skin test antigen: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Coccidioides immitis spherule-derived skin test antigen: Drug information</div><div class="clear"></div><div id="topicText">For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F26598461"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Skin test response</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The expected response to <i>Coccidioides immitis</i> skin test is a local area of inflammation at the site of the skin test. The reaction is usually dime to quarter size reaching maximum diameter between 24 and 48 hours. Larger accelerated reactions can occur, which may require treatment with local cold compresses and anti-inflammatory medication. </p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Systemic reactions can occur with skin test antigens and in certain individuals these reactions may be life-threatening or cause death. Emergency measures and personnel trained in their use should be immediately available. Patients should be observed for at least 20 minutes following the administration of a skin test. </p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Appropriate use</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Coccidioides immitis</i> skin test should never be given intravenously.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Reporting of adverse reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">To report SUSPECTED ADVERSE REACTIONS contact the manufacturer at (855) 855-1212 or MEDWATCH, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20852, Telephone: (800) 332-1088 or <a href="/external-redirect?target_url=http%3A%2F%2Fvaers.hhs.gov%2Findex&amp;token=dJuRidyjQYZxq9fkueW6qyWTvn%2Fp9jDJLlDYcIYjX1yIn9pmTuN0f%2BLI7X4NwNtw&amp;TOPIC_ID=98580" target="_blank">www.vaers.hhs.gov</a>.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26341138"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Spherusol</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55918607"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diagnostic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F26598471"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="054781fc-b4ed-42aa-af3d-4c6fd8e37688">
<i>Coccidioides immitis</i> skin test antigen</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Coccidioides immitis</i> skin test antigen:</b> Intradermal: 0.1 mL; repeat administration has not been evaluated.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991967"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989313"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F240761"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported following concomitant injections with other skin test extracts, product diluent, and saline; frequencies may not be specific to the <i>Coccidioides immitis</i> antigen.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Local: Itching at injection site (85%), swelling at injection site (79%), pain at injection site (17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased heart rate (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (2%) , fatigue (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin ulceration at injection site (including necrosis, 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal symptoms (nausea/cramps, 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (2%), injection site reaction (sensitivity, 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (6%), arthralgia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (7%), cough (2%)</p></div>
<div class="block coi drugH1Div" id="F240771"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe allergic reaction (eg, anaphylaxis) to <i>Coccidioides immitis</i> skin test, or any component of the formulation, or other coccidioidin products.</p></div>
<div class="block war drugH1Div" id="F240759"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: <b>[US Boxed Warning]: Systemic reactions can occur with skin test antigens and may be life-threatening (some fatal).</b> Observe patients for at least 30 minutes after an injection in case an immediate hypersensitivity reaction occurs; resuscitative equipment and medications to manage anaphylactic reactions should be available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Any condition or agent that impairs or attenuates delayed-type hypersensitivity reactions, including infections and use of immunosuppressive drugs, can potentially cause a false negative reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <b>[US Boxed Warning]: Do not administer intravenously.</b> The use of <i>Coccidioides immitis</i> skin test to detect delayed-type hypersensitivity response in the general population with unknown exposure to <i>Coccidioides immitis</i> has not been evaluated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin test response: <b>[US Boxed Warning]: The expected response is local inflammation at the site of the skin test. This reaction is usually a dime to quarter in size, reaching maximum diameter between 24 and 48 hours; larger accelerated reactions can occur, which may require treatment with local cold compresses and anti-inflammatory medication.</b> Individuals with acute or disseminated coccidioidomycosis or individuals with immunodeficiency and a history of coccidioidomycosis may not develop a delayed-type hypersensitivity response.</p></div>
<div class="block foc drugH1Div" id="F240768"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intradermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Spherusol: 127 mcg/0.1 mL (1 mL) [contains phenol, thimerosal (thiomersal)]</p></div>
<div class="block geq drugH1Div" id="F240755"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26597077"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Spherusol Intradermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">127 mcg/0.1 mL (per mL): $1,380.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F26609888"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Intradermal: Inject intradermally in the volar surface of forearm using a tuberculin syringe (0.5 or 1 mL) and a <sup>1</sup>/<sub>2</sub>" 26- or 27-gauge needle.</p>
<p style="text-indent:-2em;margin-left:2em;">Positive reaction: Induration of 5 mm or more (usually 5 to 10 mm in diameter and dime to quarter in size); assess for induration at 48 hours following administration. An immediate reaction (15 minutes to 1 hour following administration and persisting for up to 24 hours) may occur in some patients; however, these wheals do not represent a positive reaction (Wack 2015).</p></div>
<div class="block use drugH1Div" id="F240769"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>
<i>Coccidioides immitis</i> skin test antigen:</b>  For detection of delayed-type hypersensitivity to <i>Coccidioides immitis</i> in individuals 18 to 64 years of age with a history of pulmonary coccidioidomycosis.</p></div>
<div class="block cyt drugH1Div" id="F13299073"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F240762"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the diagnostic effect of Coccidioides immitis Skin Test. Management: Consider discontinuing systemic corticosteroids (dosed at 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks) several weeks prior to coccidioides immitis skin antigen testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the diagnostic effect of Coccidioides immitis Skin Test. Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the diagnostic effect of Coccidioides immitis Skin Test. Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the diagnostic effect of Coccidioides immitis Skin Test. Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the diagnostic effect of Coccidioides immitis Skin Test. Management: Consider discontinuing methotrexate several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F26598462"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block brc drugH1Div" id="F26598464"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if <i>Coccidioides immitis</i> antigen is excreted in breast milk. The manufacturer recommends that caution be exercised when administering to a nursing women.</p></div>
<div class="block mop drugH1Div" id="F26598475"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hypersensitivity reactions (30 minutes after injection)</p></div>
<div class="block pha drugH1Div" id="F26598467"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;">Elicits a cellular immune reaction to <i>Coccidioides immitis</i>, as evidenced by a delayed-type hypersensitivity (DTH) response to coccidioidin based on the interaction of antigen with CD4 and CD8 lymphocytes followed by the secretion of interleukins and other lymphokines from macrophage cells. The release of effector molecules causes endothelial cells lining the blood vessels to become permeable and allows fibrinogen to escape into the surrounding tissue where it is converted to fibrin. The deposition of fibrin and the accumulation of T-cells and monocytes within the extracellular spaces cause the tissue to swell and become indurated.</p></div>
<div class="block phk drugH1Div" id="F26598469"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Time to peak: 48 hours</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Spherusol (<i>Coccidioides immitis</i> spherule-derived skin test antigen) [prescribing information]. San Diego, CA: Nielsen BioSciences; May 2017.</div>
</li>
<li>
<div class="reference">
                  Wack EE, Ampel NM, Sunenshine RH, Galgiani JN. The return of delayed-type hypersensitivity skin testing for coccidioidomycosis. <i>Clin Infect Dis</i>. 2015;61(5):787-791.</div>
</li></ol></div><div id="topicVersionRevision">Topic 98580 Version 46.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
